A federal review is underway that could reclassify 14 peptides into FDA Category 1. This change that may influence how peptide therapies are accessed in the U.S. Here's what experts are Q1 2026 Recap: Top FDA Approvals HCPLive FDA Launches Framework to Accelerate Individualized Therapies for Ultra Rare Diseases 2026 OncoDaily Innovative Biologics Expected Biologic Drug Approvals in 2026 Big news for peptides! In July, the FDA will meet to evaluate the most commonly used peptides for FDA authorized compounding.